WallStSmart

Caring Brands, Inc. Common Stock (CABR)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 164083032019% more annual revenue ($4.51T vs $2,746). CABR leads profitability with a 0.0% profit margin vs -3.4%. TAK earns a higher WallStSmart Score of 57/100 (C).

CABR

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 5/9Altman Z: -5.82

TAK

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 1.20

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CABR0 strengths · Avg: 0/10

No standout strengths identified

TAK3 strengths · Avg: 10.0/10
PEG RatioValuation
0.4010/10

Growing faster than its price suggests

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
330.2%10/10

Earnings expanding 330.2% YoY

Areas to Watch

CABR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.91M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-217.1%2/10

ROE of -217.1% — below average capital efficiency

TAK4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Free Cash FlowQuality
$-26.01B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CABR

CABR has a balanced fundamental profile.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.

Bear Case : CABR

The primary concerns for CABR are EPS Growth, Market Cap, Profit Margin.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

CABR profiles as a value stock while TAK is a turnaround play — different risk/reward profiles.

TAK is growing revenue faster at 3.9% — sustainability is the question.

CABR generates stronger free cash flow (-550,794), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TAK scores higher overall (57/100 vs 15/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caring Brands, Inc. Common Stock

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Caring Brands, Inc., a wellness consumer products company, provides over-the-counter and cosmetic consumer products. The company is headquartered in Fort Pierce, Florida.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?